Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.

ABSTRACT:

Objective

The management of complex patients with neuroimmunological diseases is hindered by an inability to reliably measure intrathecal inflammation. Currently implemented laboratory tests developed >40 years ago either are not dynamic or fail to capture low levels of central nervous system (CNS) inflammation. Therefore, we aimed to identify and validate biomarkers of CNS inflammation in 2 blinded, prospectively acquired cohorts of untreated patients with neuroimmunological diseases and embedded controls, with the ultimate goal of developing clinically useful tools.

Methods

Because biomarkers with maximum utility reflect immune phenotypes, we included an assessment of cell specificity in purified primary immune cells. Biomarkers were quantified by optimized electrochemilum

SUBMITTER: Komori M 

PROVIDER: S-EPMC5568079 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature